Tenecteplase


Concise Prescribing Info
Indications/Uses
Acute MI.
Dosage/Direction for Use
Adult : IV 30-50 mg as single bolus dose depending on body wt as soon as possible after onset of symptoms. Max: 50 mg.
Dosage Details
Intravenous
Acute myocardial infarction
Adult: 30-50 mg as a single bolus dose over 5-10 sec as soon as possible after the onset of symptoms. The dose is based on body weight. Max: 50mg.
Incompatibility
Dextrose solution.
Contraindications
Patients at risk of cerebral bleeding including severe hypertension, history of stroke, intracranial or intraspinal surgery or trauma within 2 mth, arteriovenous malformation or aneurysm, cerebral neoplasm. Haemorrhage or known bleeding diathesis.
Special Precautions
Patients with increased risk of bleeding. Recent history of GI or genitourinary bleed, recent major surgery, previous puncture of noncompressible vessels, hypertension (>180/110 mm Hg), high risk of left heart thrombus, acute pericarditis, subacute bacterial endocarditis, coagulation defects, invasive procedures, haemorrhagic ophthalmic conditions. Elderly, pregnancy and lactation. Severe hepatic impairment.
Adverse Reactions
Haemorrhage, fever, nausea, vomiting, allergic reactions, hypotension.
Potentially Fatal: Severe internal bleeding.
Drug Interactions
Increased risk of haemorrhage with heparin, oral anticoagulants, antiplatelet drugs and other drugs that can affect platelet function.
Lab Interference
Results of coagulation tests and/or measures of fibrinolytic activity may be inaccurate as tenecteplase remains active under in vitro conditions.
Action
Description: Tenecteplase is a biosynthetic form of the enzyme human tissue-type plasminogen activator (t-PA). It is a fibrin-specific thrombolytic, converts plasminogen to plasmin, a proteolytic enzyme that has fibrinolytic effects.
Pharmacokinetics:
Distribution: Terminal half-life: 90-130 min.
Metabolism: Mainly cleared by hepatic metabolism
Storage
Store at <30°C or under refrigeration (2- 8°C). Reconstituted solution: store at 2-8°C and used within 8 hr.
Disclaimer: This information is independently developed by MIMS based on Tenecteplase from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in